HuGE Literature Finder
Records
1
-
21
| Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes. Cancer medicine 2021 Feb . Yan Xuefen, Wang Lu, Jiang Lingxu, Luo Yingwan, Lin Peipei, Yang Wenli, Ren Yanling, Ma Liya, Zhou Xinping, Mei Chen, Ye Li, Xu Gaixiang, Xu Weilai, Yang Haiyang, Lu Chenxi, Jin Jie, Tong Hongy |
| Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Experimental hematology & oncology 2020 9 2. Yu Jifeng, Li Yingmei, Li Tao, Li Yafei, Xing Haizhou, Sun Hui, Sun Ling, Wan Dingming, Liu Yanfang, Xie Xinsheng, Jiang Zhongxi |
| Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct . Zhu Guo, Nafa Khedoudja, Agaram Narasimhan, Zehir Ahmet, Benayed Ryma, Sadowska Justyna, Borsu Laetitia, Kelly Ciara, Tap William D, Fabbri Nicola, Athanasian Edward, Boland Patrick J, Healey John H, Berger Michael F, Ladanyi Marc, Hameed Mee |
| The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML. American journal of hematology 2019 May . Dunlap Jennifer B, Leonard Jessica, Rosenberg Mara, Cook Rachel, Press Richard, Fan Guang, Raess Philipp, Druker Brian J, Traer El |
| Prognostic utility of six mutated genes for older patients with acute myeloid leukemia. International journal of cancer 2018 04 142 (8): 1664-1670. Wang Jinghan, Ma Zhixin, Wang Qinrong, Guo Qi, Huang Jiansong, Yu Wenjuan, Wang Huanping, Huang Jingwen, Washington Shao Yang, Chen Suning, Jin J |
| Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. Hematological oncology 2016 Jun . Saillard Colombe, Guermouche Helene, Derrieux Coralie, Bruneau Julie, Frenzel Laurent, Couronne Lucile, Asnafi Vahid, Macintyre Elizabeth, Trinquand Amélie, Lhermitte Ludovic, Molina Thierry, Suarez Felipe, Lemonnier Francois, Kosmider Olivier, Delarue Richard, Hermine Olivier, Cheminant Morga |
| A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecologic oncology 2016 Apr 141 (1): 108-12. Penson R T, Sales E, Sullivan L, Borger D R, Krasner C N, Goodman A K, Del Carmen M G, Growdon W B, Schorge J O, Boruta D M, Castro C M, Dizon D S, Birrer M |
| Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American journal of hematology 2016 Apr . Rotunno Giada, Pacilli Annalisa, Artusi Valentina, Rumi Elisa, Maffioli Margherita, Delaini Federica, Brogi Giada, Fanelli Tiziana, Pancrazzi Alessandro, Pietra Daniela, Bernardis Isabella, Belotti Clara, Pieri Lisa, Sant'Antonio Emanuela, Salmoiraghi Silvia, Cilloni Daniela, Rambaldi Alessandro, Passamonti Francesco, Barbui Tiziano, Manfredini Rossella, Cazzola Mario, Tagliafico Enrico, Vannucchi Alessandro M, Guglielmelli Pao |
| Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro-oncology 2015 Sep . Dubbink Hendrikus J, Atmodimedjo Peggy N, Kros Johan M, French Pim J, Sanson Marc, Idbaih Ahmed, Wesseling Pieter, Enting Roelien, Spliet Wim, Tijssen Cees, Dinjens Winand N M, Gorlia Thierry, van den Bent Martin |
| Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015 May 28 (5): 706-14. Ohgami Robert S, Ma Lisa, Merker Jason D, Gotlib Jason R, Schrijver Iris, Zehnder James L, Arber Daniel |
| A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. British journal of haematology 2015 Apr 169 (1): 71-6. Wassie Emnet, Finke Christy, Gangat Naseema, Lasho Terra L, Pardanani Animesh, Hanson Curtis A, Ketterling Rhett P, Tefferi Ayal |
| High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia 2014 Jul 28 (7): 1449-58. Krauth M-T, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger |
| Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis. Leukemia & lymphoma 2012 Dec 53 (12): 2423-9. Zhou Kuang-Guo, Jiang Li-Jun, Shang Zhen, Wang Jue, Huang Liang, Zhou Jian-Fe |
| Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting. The Journal of molecular diagnostics : JMD 2012 Aug . Ibañez M, Such E, Cervera J, Luna I, Gomez-Seguí I, Lopez-Pavía M, Dolz S, Barragan E, Fuster O, Llop M, Rodriguez-Veiga R, Avaria A, Oltra S, Leonor Senent M, Moscardó F, Montesinos P, Martinez-Cuadrón D, Martín G, Sanz MA |
| Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Journal of hematology & oncology 2012 5 (1): 5. Chotirat Sadudee, Thongnoppakhun Wanna, Promsuwicha Orathai, Boonthimat Chetsada, Auewarakul Chirayu |
| Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PloS one 2012 7 (8): e43090. Traina Fabiola, Visconte Valeria, Jankowska Anna M, Makishima Hideki, O'Keefe Christine L, Elson Paul, Han Yingchun, Hsieh Fred H, Sekeres Mikkael A, Mali Raghuveer Singh, Kalaycio Matt, Lichtin Alan E, Advani Anjali S, Duong Hien K, Copelan Edward, Kapur Reuben, Olalla Saad Sara T, Maciejewski Jaroslaw P, Tiu Ramon |
| Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011 Nov 118 (20): 5593-603. Shen Yang, Zhu Yong-Mei, Fan Xing, Shi Jing-Yi, Wang Qin-Rong, Yan Xiao-Jing, Gu Zhao-Hui, Wang Yan-Yan, Chen Bing, Jiang Chun-Lei, Yan Han, Chen Fei-Fei, Chen Hai-Min, Chen Zhu, Jin Jie, Chen Sai-Ju |
| CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011 May 117 (21): e198-206. Makishima Hideki, Jankowska Anna M, McDevitt Michael A, O'Keefe Christine, Dujardin Simon, Cazzolli Heather, Przychodzen Bartlomiej, Prince Courtney, Nicoll John, Siddaiah Harish, Shaik Mohammed, Szpurka Hadrian, Hsi Eric, Advani Anjali, Paquette Ronald, Maciejewski Jaroslaw |
| Benefits of interferon-ß and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer 2011 Apr 117 (8): 1721-30. Motomura Kazuya, Natsume Atsushi, Kishida Yugo, Higashi Hiroyuki, Kondo Yutaka, Nakasu Yoko, Abe Tatsuya, Namba Hiroki, Wakai Kenji, Wakabayashi Toshihi |
| Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta neuropathologica 2010 Dec 120 (6): 719-29. Metellus Philippe, Coulibaly Bema, Colin Carole, de Paula Andre Maues, Vasiljevic Alexandre, Taieb David, Barlier Anne, Boisselier Blandine, Mokhtari Karima, Wang Xiao Wei, Loundou Anderson, Chapon Frederique, Pineau Sandrine, Ouafik L'Houcine, Chinot Olivier, Figarella-Branger Dominiq |
| IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology 2009 Aug 11 (4): 341-7. Ichimura Koichi, Pearson Danita M, Kocialkowski Sylvia, Bäcklund L Magnus, Chan Raymond, Jones David T W, Collins V Pet |
- Page last reviewed:Oct 1, 2021
- Page last updated:Oct 20, 2021
- Content source: